Related Experiment Video
Updated: May 12, 2026
High-Throughput Total Internal Reflection Fluorescence and Direct Stochastic Optical Reconstruction Microscopy Using a Photonic Chip
Published on: November 16, 2019
Cost-Effectiveness Analysis of a Maternal Vaccination Program Against Respiratory Syncytial Virus in Norway
Susanne Gerda Værnø1, Francisco Oteiza1, Maren Gillebo1
1Oslo Economics, Oslo, Norway.
Insights
Maternal vaccination with the RSVpreF vaccine is a cost-effective strategy for preventing respiratory syncytial virus (RSV) infections in Norwegian infants. This approach reduces hospital admissions and healthcare visits, offering significant value from both societal and healthcare perspectives.
Area of Science:
- Public Health
- Vaccinology
- Health Economics
Background:
- Respiratory syncytial virus (RSV) is a leading cause of infant hospitalizations globally.
- The novel RSVpreF maternal vaccine demonstrates efficacy in reducing severe RSV infections in infants.
- Healthcare systems face substantial burdens due to RSV-related illnesses in children.
Purpose of the Study:
- To assess the cost-effectiveness of the RSVpreF maternal vaccination program in Norway.
- To evaluate the impact of seasonal cost variations on the intervention's economic value.
- To compare a seasonal maternal vaccination strategy against no intervention.
Main Methods:
- A Markov model was employed to simulate clinical outcomes, costs, and quality-adjusted life years.
- The analysis considered a hypothetical cohort of Norwegian infants born within a single RSV season.
- Incremental cost-effectiveness ratios (ICERs) were calculated from healthcare and societal perspectives.
Main Results:
- Seasonal maternal RSVpreF vaccination is cost-effective in Norway, aligning with the national willingness-to-pay threshold.
- The program is projected to prevent 27% of RSV hospital admissions and reduce primary care and outpatient visits.
- Seasonal variations in hospitalization costs significantly impact the ICER, potentially making the intervention dominant from a societal viewpoint.
Conclusions:
- The RSVpreF maternal vaccination program is a cost-effective public health intervention in Norway.
- The vaccine's list price supports its cost-effectiveness from both healthcare and societal perspectives.
- A willingness-to-pay threshold of 500,000 NOK confirms the program's economic viability.
Background:
Respiratory syncytial virus (RSV) is recognized as the primary cause of hospitalizations among children with lower respiratory tract infections in developed countries, placing a significant burden on both patients and healthcare systems. The efficacy, safety, and immunogenicity of maternal vaccination with the novel RSVpreF vaccine have been evaluated in a Phase III clinical trial, showing a decreased risk of severe infection in infants. Our study assesses the cost-effectiveness of the RSVpreF vaccine and seasonal variation of costs in a Norwegian setting.
Methods:
A Markov model was used to estimate the clinical outcomes, costs, and quality-adjusted life years of a hypothetical cohort of Norwegian infants born during a single RSV season. A seasonal vaccination program with RSVpreF vaccine was compared to no intervention by means of an incremental cost-effectiveness ratio (ICER) from extended healthcare and societal perspectives.
Results:
A seasonal maternal vaccination program with RSVpreF in Norway is cost-effective from both a healthcare and societal perspective, given the Norwegian willingness-to-pay threshold range. The program could prevent 27% of the yearly RSV-associated hospital admissions, as well as 14% and 24% of the yearly RSV-associated primary care and outpatient visits. A 10% increase/decrease in hospitalization costs during the winter/summer months leads to a 26% reduction in the ICER from a healthcare perspective and turns the intervention into a dominant strategy from a societal one.
Conclusions:
Based on the RSVpreF vaccine's list price in Norway, the seasonal vaccination program is cost-effective from both the healthcare and societal perspectives, considering a willingness-to-pay threshold of 500,000 NOK.
More Related Videos
08:04Measuring Mitochondrial Electron Transfer Complexes in Previously Frozen Cardiac Tissue from the Offspring of Sow: A Model to Assess Exercise-Induced Mitochondrial Bioenergetics Changes
Published on: August 16, 2021
12:06Analyzing Mitochondrial Morphology Through Simulation Supervised Learning
Published on: March 3, 2023
